Small molecule drugs account for nearly 90% of the contemporary therapeutics pipeline. In fact, in 2019, the FDA’s Center for Drug Evaluation and Research approved 48 small molecule drugs, representing 70% of the new molecular entities (NMEs) clearing regulatory review in the same year.
Ciccc Vancouver
Kubet11
Nha Cai Vn88
Gupta Bikaneri Sweets
99ok
Hi88
Shelby Towing Of Scituate
Top88
80jili
Azaria Pearl